Stetz Gary S. purchased $100K of CTRVP
Stetz Gary S. (Interim CEO) purchased 2,000,000 shares of Hepion Pharmaceuticals, Inc. (CTRVP) at $0.05 ($0.10M total) on 2026-08-03.
How this was made
The 30-second read
Why it matters
The newest fact is the interim CEO’s open-market purchase of 2,000,000 shares at $0.0500, totaling $100,000, with holdings after the trade of 3,250,000 shares.
Market read
Traders may view the insider buy as a small sentiment tailwind, but there is no accompanying fundamental update in the text.
What to watch
The filing states no pre-arranged 10b5-1 plan, but the article does not disclose whether the purchase was part of compensation, tax planning, or other non-informational motives.
Background
The article is an SEC Form 4 insider transaction disclosure for Hepion Pharmaceuticals, Inc.
Ticker impact
Form 4 shows interim CEO Gary S. Stetz bought 2,000,000 shares of Hepion Pharmaceuticals at $0.0500 on 2026-08-03.
Likely limited near-term impact; any effect would be sentiment-driven rather than earnings or trial-driven.
The filing is a primary-source insider transaction with clear size and price, but the article provides no accompanying operational update, guidance, or clinical/regulatory milestone.
Market effects
Minimal; this is company-specific insider activity with no sector-wide regulatory or trial read-through provided.
None indicated.
None indicated.
Counterpoint
Insider purchases can be routine liquidity or diversification actions and do not guarantee near-term operational improvement.
Key entities
- issuerHepion Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure (CTRVP).
- insiderGary S. Stetz
Interim CEO, officer and director, reported an open-market purchase.